# Synergistic Effects of Obesity and Hyperglycemia on Hippocampal Neurodegenerative Decline Disrupt the Neural Circuitry Regulating Motivation in Zucker Diabetic Fatty Rats

**Authors:** Martha Patricia Islas-Islas, Aleida Monserrat Coss-Orozco, Diana Moroni-González, Erick Flores-Cholula, José Everardo Avelino-Cruz, Julio Cesar Morales-Medina, Alfonso Diaz, Fabián Galindo-Ramírez, Samuel Treviño, Rubén Antonio Vázquez-Roque

PMC · DOI: 10.3390/metabo16020107 · 2026-02-03

## TL;DR

This study shows that obesity and high blood sugar together cause early brain changes in rats, leading to memory and movement problems.

## Contribution

The study reveals the synergistic impact of obesity and hyperglycemia on hippocampal neurodegeneration and cognitive decline in a rat model.

## Key findings

- Obesity and hyperglycemia together cause significant memory loss and hippocampal neuron loss in rats.
- Hyperglycemia worsens recognition memory and increases oxidative stress in the hippocampus.
- Obesity alone reduces motor activity and hippocampal neuronal density.

## Abstract

Background/Objectives: Type 2 diabetes (T2D) and obesity are chronic metabolic disorders associated with cognitive impairment and neuronal damage. The hippocampus, a region sensitive to nutrient excess, is critical for integrating sensory and metabolic signals. This study aimed to determine the early onset of cognitive and motor deficits induced by obesity and/or hyperglycemia and to characterize associated hippocampal alterations in Zucker Diabetic Fatty (ZDF) rats. Methods: Male ZDF rats (13 weeks old) were categorized into three groups: lean control, obese normoglycemic (ZDF-NG), and obese hyperglycemic (ZDF-HG). Assessments included zoometric parameters (weight and adiposity), biochemical assays (glucose tolerance, insulin response, and lipid profile), and behavioral tests (Open Field and Novel Object Recognition). Hippocampal health was evaluated through stereological neuronal density analysis and redox balance markers. Results: Both obese groups exhibited significant visceral adiposity and hyperlipidemia. The ZDF-HG group was further characterized by glucose intolerance, hepatic insulin resistance, and reduced β-cell function. Behavioral results showed that while obesity decreased motor activity, hyperglycemia significantly exacerbated the loss of both short- and long-term recognition memory. Histologically, obesity was associated with decreased neuronal density in the hippocampal DG and CA1 regions. Furthermore, hippocampal ROS was significantly elevated in the ZDF-HG group, and glutathione reductase activity was reduced in both obese phenotypes. Conclusions: The findings demonstrate that obesity initiates hippocampal neurodegeneration and motor decline, and that hyperglycemia severely impairs recognition memory. These results emphasize the critical interplay between metabolic dysfunction and cognitive decline, highlighting the necessity of managing both obesity and T2D to prevent early neurodegenerative changes.

## Linked entities

- **Diseases:** Type 2 diabetes (MONDO:0005148), obesity (MONDO:0011122)

## Full-text entities

- **Genes:** Syp (synaptophysin) [NCBI Gene 20977] {aka A230093K24Rik, Syn, p38}, Hpgds (hematopoietic prostaglandin D synthase) [NCBI Gene 58962] {aka Ptgds2}, CAT (catalase) [NCBI Gene 847], SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, Srebf1 (sterol regulatory element binding transcription factor 1) [NCBI Gene 78968] {aka ADD-1, ADD1, SREBP-1, SREBP-1c, Srebp1}, Adipoq (adiponectin, C1Q and collagen domain containing) [NCBI Gene 246253] {aka Acdc, Acrp30, Adid}, Gsta4 (glutathione S-transferase alpha 4) [NCBI Gene 300850], Tnf (tumor necrosis factor) [NCBI Gene 24835] {aka RATTNF, TNF-alpha, Tnfa}, Il1b (interleukin 1 beta) [NCBI Gene 24494] {aka IL-1F2}, Lepr (leptin receptor) [NCBI Gene 24536] {aka Fa}, Lep (leptin) [NCBI Gene 25608] {aka OB, obese}, Cat (catalase) [NCBI Gene 24248] {aka CS1, Cas1, Cat01, Catl, Cs-1}, Gsr (glutathione-disulfide reductase) [NCBI Gene 116686], Ca3 (carbonic anhydrase 3) [NCBI Gene 54232] {aka Car3}, Il6 (interleukin 6) [NCBI Gene 24498] {aka ILg6, Ifnb2}, Gsk3b (glycogen synthase kinase 3 beta) [NCBI Gene 84027]
- **Diseases:** hippocampal damage (MESH:D000092223), neural death (MESH:D003643), Fasting hyperinsulinemia (MESH:D006946), hippocampal dysfunction (MESH:D001927), hyperglycemic (MESH:D006944), leptin resistance (OMIM:614962), IR (MESH:D007333), adiposity (MESH:D018205), impulsivity (MESH:D007174), neuronal damage (MESH:D009410), T2D (MESH:D003924), T1D (MESH:D003922), beta-cell dysfunction (MESH:D007340), glucose intolerance (MESH:D018149), abdominal obesity (MESH:D056128), impaired executive and motor functions (MESH:D000068079), impaired memory and executive function (MESH:D008569), neuropathy (MESH:D009422), Cognitive and motor regions dysfunction (MESH:D003072), Hyperglycemia (MESH:D006943), metabolic syndrome (MESH:D024821), loss (MESH:D016388), hyperlipidemia (MESH:D006949), inflammation (MESH:D007249), injury to (MESH:D014947), Neurodegenerative (MESH:D019636), muscle (MESH:D019042), dyslipidemia (MESH:D050171), anhedonia (MESH:D059445), Diabetic Fatty (MESH:D003920), neuroinflammation (MESH:D000090862), hippocampal atrophy (MESH:D001284), Obesity (MESH:D009765), overweight (MESH:D050177), hyperphagia (MESH:D006963), diminished horizontal and vertical movement (MESH:D009759), diabetic encephalopathy (MESH:C000721848), metabolic diseases (MESH:D008659), visceral adiposity (MESH:D007418), loss of muscle mass (MESH:C536030)
- **Chemicals:** Antioxidant Enzyme (-), hydroperoxides (MESH:D006861), HEPES (MESH:D006531), sulfanilamide (MESH:D000077145), Nitrite (MESH:D009573), NADPH (MESH:D009249), selenium (MESH:D012643), carbohydrates (MESH:D002241), FAs (MESH:D005227), MDA (MESH:D008315), GSSG (MESH:D019803), Ketamine (MESH:D007649), DIA (MESH:C076868), GSH (MESH:D005978), Lipid (MESH:D008055), PFA (MESH:C003043), sucrose (MESH:D013395), methanesulfonic acid (MESH:C045880), PBS (MESH:D007854), 1-chloro-2,4-dinitrobenzene (MESH:D004137), ROS (MESH:D017382), Glucose (MESH:D005947), methanol (MESH:D000432), zinc (MESH:D015032), phosphate (MESH:D010710), 1-methyl-2-phenylindole (MESH:C520322), nitrogen (MESH:D009584), EDTA (MESH:D004492), Xylazine (MESH:D014991), tert-butyl hydroperoxide (MESH:D020122), sodium nitrite (MESH:D012977), Triglycerides (MESH:D014280), acetonitrile (MESH:C032159), sodium azide (MESH:D019810), water (MESH:D014867), 2',7'-dichlorofluorescein (MESH:C037631), acetylcholine (MESH:D000109), 2',7'-dichlorofluorescein diacetate (MESH:C029569), Griess reagent (MESH:C095000), glycogen (MESH:D006003), FFA (MESH:D005230), glutamate (MESH:D018698), N-(1-naphthyl) ethylenediamine dihydrochloride (MESH:C008588), cresyl violet (MESH:C028911), DTNB (MESH:D004228), acetic acid (MESH:D019342), noradrenaline (MESH:D009638), blood glucose (MESH:D001786), NO (MESH:D009569), cholesterol (MESH:D002784)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12942438/full.md

---
Source: https://tomesphere.com/paper/PMC12942438